Explore

Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives
Trendline Trendline
BioLife Solutions Reports 25% Revenue Increase in Q1 2026, Strengthening Market Position

BioLife Solutions Reports 25% Revenue Increase in Q1 2026, Strengthening Market Position

BioLife Solutions Reports 25% Revenue Increase in Q1 2026, Strengthening Market Position
Trendline Trendline
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Trendline Trendline
Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics for Enzyme Therapy Development

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics for Enzyme Therapy Development

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics for Enzyme Therapy Development
Trendline Trendline
Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals
Trendline Trendline
Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals
Trendline Trendline
Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast
Trendline Trendline
Ascletis Pharma to Present Innovative Obesity Treatment Data at European Congress

Ascletis Pharma to Present Innovative Obesity Treatment Data at European Congress

Ascletis Pharma to Present Innovative Obesity Treatment Data at European Congress
Trendline Trendline
Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD
Trendline Trendline
GSK Licenses siRNA Drug from China's SiranBio in $1 Billion Deal to Target Cardiometabolic Diseases

GSK Licenses siRNA Drug from China's SiranBio in $1 Billion Deal to Target Cardiometabolic Diseases

GSK Licenses siRNA Drug from China's SiranBio in $1 Billion Deal to Target Cardiometabolic Diseases